Adding group psychotherapy to medication treatment in dysthymia: A randomized prospective pilot study

Journal of Psychotherapy Practice and Research

Volumn 10, Issue 2, 2001, Pages 93-103

  Hellerstein, D J ^a   Little, S A S ^a   Samstag, L W ^a   Batchelder, S ^a   Christopher Muran, J ^a   Fedak, M ^a   Kreditor, D ^a   Rosenthal, R N ^a   Winston, R ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DYSTHYMIA; FEMALE; FOLLOW UP; GROUP THERAPY; HUMAN; INTERPERSONAL COMMUNICATION; MALE; RANDOMIZED CONTROLLED TRIAL; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DYSTHYMIC DISORDER; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHOTHERAPY, GROUP; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0035078120     PISSN: 1055050X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. The epidemiology of dysthymia in five communities: Rates, risks, comorbidity, and treatment
2. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
3. Dysthymia in clinical practice: Course, outcome and impact on the community
4. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses
5. Social adjustment in dysthymia, double depression and episodic major depression
6. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization
7. Psychological therapies
8. Summary of the DSM-IV Mood Disorders Field Trial and issue overview
9. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
10. Imipramine for treatment of chronic depression
11. The treatment of chronic depression, part 2: A double-blind, randomized trial of sertraline and imipramine
12. A randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia
13. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia
14. Long-term follow-up of chronic depression treated with imipramine
15. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes
16. Social impairment in dysthymia
17. Psychotherapy of dysthymia
18. Cognitive-behavior therapy for chronically depressed patients: A controlled pilot study
19. A pilot study of the cognitive treatment of dysthymic disorder
20. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder
21. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments
22. Psychotherapy of the postdysthymic patient
23. Psychotherapy for dysthymia: A naturalistic study of ten patients
24. Cost effectiveness of individual vs. group cognitive behavior therapy for problems of depression and anxiety in an HMO population
25. Group versus individual cognitive therapy: A pilot study
26. The efficacy of group and individual cognitive therapy for mild depression
27. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients
28. Integrated outpatient treatment for substance-abusing schizophrenics: A prospective study
29. When is the combination of psychotherapy and pharmacotherapy likely to be the treatment of choice for patients with major depressive disorder
30. Integrating cognitive therapy and pharmacotherapy in the treatment of prophylaxis of depression: A novel approach
31. Psychotherapy of dysthymic disorder
32. The efficacy of cognitive therapy in depression: A treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination
33. Cognitive therapy and pharmacotherapy singly and together in the treatment of depression
34. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
35. Cognitive therapy and pharmacotherapy for depression: Singly and in combination
36. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression
37. Three-year outcomes for maintenance therapies in recurrent depression
38. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: Contributing factors
39. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy, and a combination of both
40. Differential relapse following cognitive therapy and pharmacotherapy for depression
41. Cognitive therapy and pharmacotherapy for depression: Sustained improvement over one year
42. A rating scale for depression
43. Measurement of severity and treatment response in dysthymia
44. An inventory for measuring depression
45. Construction of circumplex scales for the inventory of interpersonal problems
46. Optimism, coping and health: Assessment and implications of generalized expectancies
47. Depressive attributional style
48. Explanatory style change during cognitive therapy for unipolar depression
49. The satisfaction with life scale
50. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research
51. Prophylactic cognitive therapy for major depressive disorder